File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
  • Basic View
  • Metadata View
  • XML View
TitlePhase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
 
AuthorsLai, CL
Han, KH
Yoon, SK
Um, SH
Yuen, MF
Kim, HS
Kim, HR
Chung, HC
Kim, CR
Hsyu, P
Averett, D
Worland, S
Kim, J
 
KeywordsMedical sciences
Gastroenterology
 
Issue Date2006
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0168-8278(06)80007-3
 
AbstractBACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. …
 
DescriptionConference Reports for NATAP (National AIDS Treatment Advocacy Project)
 
ISSN0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
DOIhttp://dx.doi.org/10.1016/S0168-8278(06)80007-3
 
DC FieldValue
dc.contributor.authorLai, CL
 
dc.contributor.authorHan, KH
 
dc.contributor.authorYoon, SK
 
dc.contributor.authorUm, SH
 
dc.contributor.authorYuen, MF
 
dc.contributor.authorKim, HS
 
dc.contributor.authorKim, HR
 
dc.contributor.authorChung, HC
 
dc.contributor.authorKim, CR
 
dc.contributor.authorHsyu, P
 
dc.contributor.authorAverett, D
 
dc.contributor.authorWorland, S
 
dc.contributor.authorKim, J
 
dc.date.accessioned2010-09-25T19:47:25Z
 
dc.date.available2010-09-25T19:47:25Z
 
dc.date.issued2006
 
dc.description.abstractBACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. …
 
dc.descriptionConference Reports for NATAP (National AIDS Treatment Advocacy Project)
 
dc.description.otherThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6
 
dc.identifier.citationThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0168-8278(06)80007-3
 
dc.identifier.doihttp://dx.doi.org/10.1016/S0168-8278(06)80007-3
 
dc.identifier.epageS5
 
dc.identifier.hkuros129577
 
dc.identifier.issn0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
dc.identifier.issuesuppl. 2
 
dc.identifier.openurl
 
dc.identifier.spageS5
 
dc.identifier.urihttp://hdl.handle.net/10722/101383
 
dc.identifier.volume44
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.subjectMedical sciences
 
dc.subjectGastroenterology
 
dc.titlePhase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lai, CL</contributor.author>
<contributor.author>Han, KH</contributor.author>
<contributor.author>Yoon, SK</contributor.author>
<contributor.author>Um, SH</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<contributor.author>Kim, HS</contributor.author>
<contributor.author>Kim, HR</contributor.author>
<contributor.author>Chung, HC</contributor.author>
<contributor.author>Kim, CR</contributor.author>
<contributor.author>Hsyu, P</contributor.author>
<contributor.author>Averett, D</contributor.author>
<contributor.author>Worland, S</contributor.author>
<contributor.author>Kim, J</contributor.author>
<date.accessioned>2010-09-25T19:47:25Z</date.accessioned>
<date.available>2010-09-25T19:47:25Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>The 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/101383</identifier.uri>
<description>Conference Reports for NATAP (National AIDS Treatment Advocacy Project)</description>
<description.abstract>BACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. &#8230;</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<subject>Medical sciences</subject>
<subject>Gastroenterology</subject>
<title>Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0168-8278&amp;volume=44, suppl 2, article no. 6&amp;spage=S5&amp;epage=&amp;date=2006&amp;atitle=Phase+II+multi-centre,+dose-escalating+study+of+LB80380+(ANA380)+in+hepatitis+B+patients+with+lamivudine-resistant+YMDD+mutant+HBV</identifier.openurl>
<identifier.doi>10.1016/S0168-8278(06)80007-3</identifier.doi>
<identifier.hkuros>129577</identifier.hkuros>
<identifier.volume>44</identifier.volume>
<identifier.issue>suppl. 2</identifier.issue>
<identifier.spage>S5</identifier.spage>
<identifier.epage>S5</identifier.epage>
<publisher.place>Netherlands</publisher.place>
<description.other>The 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6</description.other>
</item>